BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9586611)

  • 1. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.
    Jiborn T; Bjartell A; Abrahamsson PA
    Urology; 1998 Apr; 51(4):585-9. PubMed ID: 9586611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
    Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
    Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
    Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
    Nordin A; Wang W; Welén K; Damber JE
    Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine differentiation in prostatic carcinoma.
    Abrahamsson PA
    Prostate; 1999 May; 39(2):135-48. PubMed ID: 10221570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
    Bonkhoff H; Fixemer T
    Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine pathogenesis in adenocarcinoma of the prostate.
    Hansson J; Abrahamsson PA
    Ann Oncol; 2001; 12 Suppl 2():S145-52. PubMed ID: 11762343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
    Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
    Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
    Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
    Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
    Krijnen JL; Bogdanowicz JF; Seldenrijk CA; Mulder PG; van der Kwast TH
    J Urol; 1997 Jul; 158(1):171-4. PubMed ID: 9186347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
    Conteduca V; Aieta M; Amadori D; De Giorgi U
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of neuroendocrine cells in prostate cancer progression].
    Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
    Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
    Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
    Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
    Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
    Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
    Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E
    Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroendocrine differentiated prostate adenocarcinoma: Report of 23 cases and review of the literature].
    Deng L; Long Z; He LY; Tang J; Liu JY; Liu B; Yao K; Zhang YC
    Zhonghua Nan Ke Xue; 2020 Jan; 26(1):42-47. PubMed ID: 33345476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.